Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes

American Journal of Cardiology

Volumn 112, Issue 5, 2013, Pages 737-745

  Berger, Jeffrey S ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; METOPROLOL; PRASUGREL; PROSTACYCLIN; PURINERGIC P2Y12 RECEPTOR; THIENOPYRIDINE DERIVATIVE; THROMBOXANE A2; TICAGRELOR;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DEATH; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 84881611663     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.04.055     Document Type: Review

References (58)

1. V.L. Roger, A.S. Go, D.M. Lloyd-Jones, R.J. Adams, J.D. Berry, T.M. Brown, M.R. Carnethon, S. Dai, G. de Simone, E.S. Ford, C.S. Fox, H.J. Fullerton, C. Gillespie, K.J. Greenlund, S.M. Hailpern, J.A. Heit, P.M. Ho, V.J. Howard, B.M. Kissela, S.J. Kittner, D.T. Lackland, J.H. Lichtman, L.D. Lisabeth, D.M. Makuc, G.M. Marcus, A. Marelli, D.B. Matchar, M.M. McDermott, J.B. Meigs, C.S. Moy, D. Mozaffarian, M.E. Mussolino, G. Nichol, N.P. Paynter, W.D. Rosamond, P.D. Sorlie, R.S. Stafford, T.N. Turan, M.B. Turner, N.D. Wong, J. Wylie-Rosett American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics-2011 update: a report from the American Heart Association Circulation 123 2011 e18 e209
2. G. Davì, and C. Patrono Platelet activation and atherothrombosis N Engl J Med 357 2007 2482 2494
3. J.W. Eikelboom, J. Hirsh, F.A. Spencer, T.P. Baglin, and J.I. Weitz Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 141 Suppl. 2 2012 e89S e119S
4. P.O. Vandvik, A.M. Lincoff, J.M. Gore, D.D. Gutterman, F.A. Sonnenberg, P. Alonso-Coello, E.A. Akl, M.G. Lansberg, G.H. Guyatt, and F.A. Spencer Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 141 Suppl. 2 2012 e637S e668S
5. C.W. Hamm, J.P. Bassand, S. Agewall, J. Bax, E. Boersma, H. Bueno, P. Caso, D. Dudek, S. Gielen, K. Huber, M. Ohman, M.C. Petrie, F. Sonntag, M.S. Uva, R.F. Storey, W. Wijns, D. Zahger, ESC Committee for Practice Guidelines, J.J. Bax, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B.A. Popescu, Z. Reiner, U. Sechtem, P.A. Sirnes, A. Torbicki, A. Vahanian, S. Windecker, Document Reviewers, S. Windecker, S. Achenbach, L. Badimon, M. Bertrand, H.E. Bøtker, J.P. Collet, F. Crea, N. Danchin, E. Falk, J. Goudevenos, D. Gulba, R. Hambrecht, J. Herrmann, A. Kastrati, K. Kjeldsen, S.D. Kristensen, P. Lancellotti, J. Mehilli, B. Merkely, G. Montalescot, F.J. Neumann, L. Neyses, J. Perk, M. Roffi, F. Romeo, M. Ruda, E. Swahn, M. Valgimigli, C.J. Vrints, and P. Widimsky ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
6. H. Jneid, J.L. Anderson, R.S. Wright, C.D. Adams, C.R. Bridges, D.E. Casey, S.M. Ettinger, F.M. Fesmire, T.G. Ganiats, A.M. Lincoff, E.D. Peterson, G.J. Philippides, P. Theroux, N.K. Wenger, and J.P. Zidar 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines J Am Coll Cardiol 60 2012 645 681
7. F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos, K. Fox, K. Huber, A. Kastrati, A. Rosengren, P.G. Steg, M. Tubaro, F. Verheugt, F. Weidinger, M. Weis, and ESC Committee for Practice Guidelines (CPG) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology Eur Heart J 29 2008 2909 2945
8. F.G. Kushner, M. Hand, S.C. Smith Jr., S.B. King 3rd, J.L. Anderson, E.M. Antman, S.R. Bailey, E.R. Bates, J.C. Blankenship, D.E. Casey Jr., L.A. Green, J.S. Hochman, A.K. Jacobs, H.M. Krumholz, D.A. Morrison, J.P. Ornato, D.L. Pearle, E.D. Peterson, M.A. Sloan, P.L. Whitlow, D.O. Williams, and American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention(updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation 120 2009 2271 2306
9. G.H. Guyatt, E.A. Akl, M. Crowther, D.D. Gutterman, H.J. Schunemann, and American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 141 Suppl. 2 2012 7S 47S
10. K.A. Fox, P.G. Steg, K.A. Eagle, S.G. Goodman, F.A. Anderson Jr., C.B. Granger, M.D. Flather, A. Budaj, A. Quill, J.M. Gore, and GRACE Investigators Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006 JAMA 297 2007 1892 1900
11. G.J. Roth, and P.W. Majerus The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein J Clin Invest 56 1975 624 632
12. C. Patrono, L.A. García Rodríguez, R. Landolfi, and C. Baigent Low-dose aspirin for the prevention of atherothrombosis N Engl J Med 353 2005 2373 2383
13. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 Lancet 2 1988 349 360
14. Antithrombotic Trialists' (ATT) Collaboration C. Baigent, L. Blackwell, R. Collins, J. Emberson, J. Godwin, R. Peto, J. Buring, C. Hennekens, P. Kearney, T. Meade, C. Patrono, M.C. Roncaglioni, and A. Zanchetti Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
15. G.G. Biondi-Zoccai, M. Lotrionte, P. Agostoni, A. Abbate, M. Fusaro, F. Burzotta, L. Testa, I. Sheiban, and G. Sangiorgi A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease Eur Heart J 27 2006 2667 2674
16. D.F. Kong, V. Hasselblad, D.E. Kandzari, L.K. Newby, and R.M. Califf Seeking the optimal aspirin dose in acute coronary syndromes Am J Cardiol 90 2002 622 625
17. C.L. Campbell, S. Smyth, G. Montalescot, and S.R. Steinhubl Aspirin dose for the prevention of cardiovascular disease: a systematic review JAMA 297 2007 2018 2024
18. C. Patrono, C. Baigent, J. Hirsh, G. Roth, and American College of Chest Physicians Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition) Chest 133 Suppl. 6 2008 199S 233S
19. J.M. Herbert, and P. Savi P2Y12, a new platelet ADP receptor, target of clopidogrel Semin Vasc Med 3 2003 113 122
20. S.D. Wiviott, E.M. Antman, and E. Braunwald Prasugrel Circulation 122 2010 394 403
21. T.A. Clarke, and L.A. Waskell The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin Drug Metab Dispos 31 2003 53 59
22. Plavix (clopidogrel) prescribing information. Available at: http://products.sanofi.us/plavix/plavix.html (last accessed March 14, 2012).
23. Plavix (clopidogrel) summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000174/WC500042189.pdf (last accessed March 14, 2012).
24. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, K.K. Fox, and Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
25. R.J. Peters, S.R. Mehta, K.A. Fox, F. Zhao, B.S. Lewis, S.L. Kopecky, R. Diaz, P.J. Commerford, V. Valentin, S. Yusuf, and Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study Circulation 108 2003 1682 1687
26. M.S. Sabatine, C.P. Cannon, C.M. Gibson, J.L. López-Sendón, G. Montalescot, P. Theroux, M.J. Claeys, F. Cools, K.A. Hill, A.M. Skene, C.H. McCabe, E. Braunwald, and CLARITY-TIMI 28 Investigators Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 2005 1179 1189
27. Z.M. Chen, L.X. Jiang, Y.P. Chen, J.X. Xie, H.C. Pan, R. Peto, R. Collins, L.S. Liu COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1607 1621
28. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, S. Gottlieb, F.J. Neumann, D. Ardissino, S. De Servi, S.A. Murphy, J. Riesmeyer, G. Weerakkody, C.M. Gibson, E.M. Antman, and TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
29. Effient (prasugrel) prescribing information. Available at: http://pi.lilly.com/us/effient.pdf (last accessed March 14, 2012).
30. Effient (prasugrel) summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000984/WC500021971.pdf (last accessed March 14, 2012).
31. Eli Lilly and Company. Cardiovascular and Renal Drugs Advisory Committee briefing document. Effient (Prasugrel). Acute coronary syndromes managed by percutaneous coronary intervention. Available at: http://www.fda.gov/ohrms/ dockets/ac/09/briefing/2009-4412b1-03-Lilly.pdf (last accessed October 12, 2012).
32. J.J. Van Giezen, L. Nilsson, P. Berntsson, B.M. Wissing, F. Giordanetto, W. Tomlinson, and P.J. Greasley Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation J Thromb Haemost 7 2009 1556 1565
33. S. Husted, and J.J. van Giezen Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist Cardiovasc Ther 27 2009 259 274
34. Brilinta (ticagrelor) prescribing information. Available at: http://www1.astrazeneca-us.com/pi/brilinta.pdf (last accessed March 13, 2012).
35. Brilique (ticagrelor) summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001241/WC500100494.pdf (last accessed March 13, 2012).
36. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, K.W. Mahaffey, B.M. Scirica, A. Skene, P.G. Steg, R.F. Storey, R.A. Harrington, PLATO Investigators, A. Freij, and M. Thorsén Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
37. K.W. Mahaffey, D.M. Wojdyla, K. Carroll, R.C. Becker, R.F. Storey, D.J. Angiolillo, C. Held, C.P. Cannon, S. James, K.S. Pieper, J. Horrow, R.A. Harrington, L. Wallentin, and PLATO Investigators Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial Circulation 124 2011 544 554
38. 12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial Am Heart J 157 2009 599 605
39. Antiplatelet Trialists' Collaboration Secondary prevention of vascular disease by prolonged antiplatelet treatment Br Med J (Clin Res Ed) 296 1988 320 331
40. P.J. Roderick, H.C. Wilkes, and T.W. Meade The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials Br J Clin Pharmacol 35 1993 219 226
41. Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 308 1994 81 106
42. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
43. D.L. Bhatt, J. Scheiman, N.S. Abraham, E.M. Antman, F.K. Chan, C.D. Furberg, D.A. Johnson, K.W. Mahaffey, E.M. Quigley, and American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Circulation 118 2008 1894 1909
44. M. Lee, B. Cryer, and M. Feldman Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury Ann Intern Med 120 1994 184 189
45. CURRENT-OASIS 7 Investigators Dose comparisons of clopidogrel and aspirin in acute coronary syndromes N Engl J Med 363 2010 930 942
46. J.S. Berger, A. Stebbins, C.B. Granger, E.M. Ohman, P.W. Armstrong, F. Van de Werf, H.D. White, R.J. Simes, R.A. Harrington, R.M. Califf, and E.D. Peterson Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy Circulation 117 2008 192 199
47. P. Patrignani, P. Filabozzi, and C. Patrono Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects J Clin Invest 69 1982 1366 1372
48. J.S. Berger, A. Lala, M.J. Krantz, G.S. Baker, and W.R. Hiatt Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials Am Heart J 162 2011 115 124
49. E.H. Awtry, and J. Loscalzo Aspirin Circulation 101 2000 1206 1218
50. S. Tickoo, M.T. Roe, E.D. Peterson, S. Milford-Beland, E.M. Ohman, W.B. Gibler, C.V. Pollack Jr., C.P. Cannon, and CRUSADE Investigators Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative Am J Cardiol 99 2007 1496 1499
51. S.S. Jolly, J. Pogue, K. Haladyn, R.J. Peters, K.A. Fox, A. Avezum, B.J. Gersh, H.J. Rupprecht, S. Yusuf, and S.R. Mehta Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study Eur Heart J 30 2009 900 907
52. AstraZeneca. Ticagrelor NDA 22-433 briefing document for cardiovascular and renal drug advisory committee meeting. Available at: http://www.fda.gov/ downloads/advisorycommittees/committeesmeetingmaterials/drugs/ cardiovascularandrenaldrugsadvisorycommittee/ucm220197.pdf (last accessed October 12, 2012).
53. T.D. Warner, S. Nylander, and C. Whatling Anti-platelet therapy: cyclooxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy Br J Clin Pharmacol 72 2011 619 633
54. N.S. Kirkby, P.D. Leadbeater, M.V. Chan, S. Nylander, J.A. Mitchell, and T.D. Warner Anti-platelet effects of aspirin vary with level of P2Y(12) receptor blockade supplied by either ticagrelor or prasugrel J Thromb Haemost 9 2011 2103 2105
55. G.H. Gislason, S. Jacobsen, J.N. Rasmussen, S. Rasmussen, P. Buch, J. Friberg, T.K. Schramm, S.Z. Abildstrom, L. Køber, M. Madsen, and C. Torp-Pedersen Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs after acute myocardial infarction Circulation 113 2006 2906 2913
56. P.C. Armstrong, P.D. Leadbeater, M.V. Chan, N.S. Kirkby, J.A. Jakubowski, J.A. Mitchell, and T.D. Warner In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation J Thromb Haemost 9 2011 552 561
57. R.S. Wright, J.L. Anderson, C.D. Adams, C.R. Bridges, D.E. Casey Jr., S.M. Ettinger, F.M. Fesmire, T.G. Ganiats, H. Jneid, A.M. Lincoff, E.D. Peterson, G.J. Philippides, P. Theroux, N.K. Wenger, J.P. Zidar, and A.K. Jacobs 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 123 2011 2022 2060
58. E.M. Antman, D.T. Anbe, P.W. Armstrong, E.R. Bates, L.A. Green, M. Hand, J.S. Hochman, H.M. Krumholz, F.G. Kushner, G.A. Lamas, C.J. Mullany, J.P. Ornato, D.L. Pearle, M.A. Sloan, S.C. Smith Jr., J.S. Alpert, J.L. Anderson, D.P. Faxon, V. Fuster, R.J. Gibbons, G. Gregoratos, J.L. Halperin, L.F. Hiratzka, S.A. Hunt, A.K. Jacobs, and J.P. Ornato ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction) J Am Coll Cardiol 44 2004 E1 E211